EASD. MiniMed 780G. Improvements in Time in Range

Skriv ut
Uppgifter
Kategori: Nyheter

The MiniMed 780G is Medtronic’s second-generation automated insulin delivery system (an upgrade from the 670G system). The device, available in Europe but still under FDA review in the US, includes automatic basal rate adjustments and correction boluses, an adjustable glucose target down to 100 mg/dl, fewer alarms, and simpler operation with the goal of further increasing Time in Range (TIR).

Real world data of the 780G in Europe shows improvements in TIR and glucose management indicator (GMI) (which can be thought of as an estimated A1C), said Prof Ohad Cohen, Medtronic’s director of Medical Affairs.

“Even with the growing number of users, more countries using it, more physicians using it, we see that these results are stable,” he said. “And when you look at six months of follow up [these results] are also sustainable, and actually there is almost no change in both the TIR and the GMI [from initiation to month six].”

The following three cohorts included 780G users across Europe who uploaded their data to CareLink between August 2020 and July 2021 and who gave permission for their data to be studied.

From www.diatribe.org

Nyhetsinfo www

red DiabetologNytt

Cohort

Results

Users with more than 10 days of data after initiating the MiniMed 780G (12,870 users)
  • 76% of users achieved a GMI less than 7%
  • 76% of users achieved a TIR greater than 70%
  • 82% of users achieved a Time Below Range (TBR) (less than 70 mg/dL) of less than 4%
  • 58% of users achieved all three of these metrics

Users with more than 10 days of data both when they were on the MiniMed 780G in “open-loop” and after using it in advanced hybrid closed-loop (2,977 users)
  • 75% of users achieved a GMI less than 7% when in closed loop (only 41% achieved this in open loop)
  • 75% of users achieved a TIR greater than 70% when in closed loop (only 36% achieved this in open loop)
  • The average sensor glucose readings decreased by 15 m/dL from 161 mg/dL in open loop to 146 mg/dL
  • Average GMI decreased by 0.4 percentage points from 7.2% in open loop to 6.8%
  • Average TIR increased by 11.4 percentage points from 64% in open loop to 76%
  • Average TBR decreased by 0.5 percentage points from 3.3% in open loop to 2.8%

Users with more than 10 days of data in each of the first six months after initiating the MiniMed 780G (2,566 users)
  • At one month, users mean sensor glucose was 143 mg/dL, GMI was 6.7%, TIR was 77% and TBR was 3%
  • These positive metrics were sustained out to six months – users mean sensor glucose was 144 mg/dL, GMI was 6.8%, TIR was 76% and TBR was 2.9%
Träffar: 931